Bolt Buys Prana Therapies, Raises $120M to Fund PRA-216
BOLT sits 35% above its 52-week low of $3.1.
Summary
Bolt is acquiring Prana Therapies and raising $120 million in a concurrent private placement to push PRA-216 into multiple inflammatory indications. The acquisition was structured as a sign-and-close reverse merger, and existing Bolt holders will be cut to roughly 6.9% of the combined company. Prana co-founder and former CEO Sheila Gujrathi will join Bolt's executive team and its board of directors. That is transformative for a company this size — Bolt had just $18.1 million in cash at Q2 and management warned in August it might not survive past Q1 2027 without new funding. The placement removes the near-term going-concern overhang and funds a pipeline asset rather than just extending runway. The deal also shifts the story from Bolt's existing oncology work toward inflammatory disease, a new therapeutic direction. Terms of the acquisition and the placement price were not disclosed in the headline.
At the time of this announcement, BOLT was trading at $4.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $3.10 to $7.20. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.